Very recently, Bacac and her colleagues have demonstrated that 2 : 1 TCB (CD20-TCB) with two anti-CD20 Fabs and one anti-CD3 epsilon subunit (CD3e) Fab, in which one of the CD20 Fabs fused directly in a “head-to-tail” fashion to the anti-CD3e Fab via a flexible linker, exhibited superior potency compared with other TCB antibodies based on the classical 1 : 1 IgG format against NHL (Figure 1(a), L) [18]. The gene discussed is CD3E; the disease is non-Hodgkin lymphoma.